EUVIMEDEUVIMED entdecken
LeserbriefKommentarOpen Access · CC BY-NC 4.0

From fibroblast foci to dense scars: PAK2-activated fibroblasts drive fibrosis progression in idiopathic pulmonary fibrosis

Xuexi Zhang, Xue Liu, Paul W Noble

European Respiratory Journal · 2025-11 · 66 (5) · 2501549

DOI: 10.1183/13993003.01549-2025 ↗

Kurz gefasst

Leserbrief in der Zeitschrift European Respiratory Journal, online erschienen am 06.11.2025. Verfasst von Xuexi Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Women's Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, NHLBI NIH HHS, American Heart Association.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extract Fibrotic diseases contribute to nearly 45% of all deaths in the developed world, affecting vital organs such as the lungs, liver, heart and kidneys. Transforming growth factor (TGF)-β is a central driver of fibrosis, promoting the activation of fibroblasts into myofibroblasts and the excessive deposition of extracellular matrix [1]. The cell-type-specific activation of p21-activated kinase 2 (PAK2) in TGF-β signalling has been recognised for some time [2, 3], but its role in fibrotic diseases has only recently come to light [4]. With great interest, we read the recent article by Watanabe et al. [5], describing a novel cellular mechanism by which PAK2 may drive fibrotic remodelling and its implication for potential therapeutic targeting in idiopathic pulmonary fibrosis (IPF). This study offers valuable insights into the distinct fibroblast populations within fibroblastic foci (FF) and dense fibrosis (DF) regions of IPF through integrated spatial and single-cell transcriptomic analysis. The authors identify PAK2 as a key fibrogenic kinase activated in FF and surrounding areas, and demonstrate that its inhibition attenuates fibrosis in a murine model, suggesting PAK2 as a promising therapeutic target.

Autor:innen und Institutionen

  • Department of Medicine and Women's Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • X. Zhang and P.W. Noble contributed equally to this article as lead authors.
  • Department of Medicine and Women's Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA Paul.Noble@cshs.org.

Förderung

  • NIA NIH HHS
  • NHLBI NIH HHS
  • American Heart Association
  • Pulmonary Fibrosis Foundation
  • Foundation for the National Institutes of Health

Zitieren

APA

Zhang, X., Liu, X., & Noble, P. W. (2025). From fibroblast foci to dense scars: PAK2-activated fibroblasts drive fibrosis progression in idiopathic pulmonary fibrosis. European Respiratory Journal, 66(5), 2501549. https://doi.org/10.1183/13993003.01549-2025

Vancouver

Zhang X, Liu X, Noble PW. From fibroblast foci to dense scars: PAK2-activated fibroblasts drive fibrosis progression in idiopathic pulmonary fibrosis. European Respiratory Journal. 2025;66(5):2501549. doi:10.1183/13993003.01549-2025

BibTeX
@article{Zhang2025,
  author = {Zhang, Xuexi and Liu, Xue and Noble, Paul W},
  title = {From fibroblast foci to dense scars: PAK2-activated fibroblasts drive fibrosis progression in idiopathic pulmonary fibrosis},
  journal = {European Respiratory Journal},
  year = {2025},
  volume = {66},
  number = {5},
  pages = {2501549},
  doi = {10.1183/13993003.01549-2025}
}
Kostenlos starten →